Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Heinzel, FR; Hohendanner, F; Jin, G; Sedej, S; Edelmann, F.
Myocardial hypertrophy and its role in heart failure with preserved ejection fraction.
J Appl Physiol (1985). 2015; 119(10):1233-1242 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Sedej Simon
Altmetrics:

Dimensions Citations:

Plum Analytics:
Number of Figures: 3
| | |
Abstract:
Left ventricular hypertrophy (LVH) is the most common myocardial structural abnormality associated with heart failure with preserved ejection fraction (HFpEF). LVH is driven by neurohumoral activation, increased mechanical load, and cytokines associated with arterial hypertension, chronic kidney disease, diabetes, and other comorbidities. Here we discuss the experimental and clinical evidence that links LVH to diastolic dysfunction and qualifies LVH as one diagnostic marker for HFpEF. Mechanisms leading to diastolic dysfunction in LVH are incompletely understood, but may include extracellular matrix changes, vascular dysfunction, as well as altered cardiomyocyte mechano-elastical properties. Beating cardiomyocytes from HFpEF patients have not yet been studied, but we and others have shown increased Ca(2+) turnover and impaired relaxation in cardiomyocytes from hypertrophied hearts. Structural myocardial remodeling can lead to heterogeneity in regional myocardial contractile function, which contributes to diastolic dysfunction in HFpEF. In the clinical setting of patients with compound comorbidities, diastolic dysfunction may occur independently of LVH. This may be one explanation why current approaches to reduce LVH have not been effective to improve symptoms and prognosis in HFpEF. Exercise training, on the other hand, in clinical trials improved exercise tolerance and diastolic function, but did not reduce LVH. Thus current clinical evidence does not support regression of LVH as a surrogate marker for (short-term) improvement of HFpEF. Copyright © 2015 the American Physiological Society.
Find related publications in this database (using NLM MeSH Indexing)
Animals -
Calcium Signaling - physiology
Heart Failure - pathology
Heart Failure - physiopathology
Humans -
Hypertrophy, Left Ventricular - pathology
Hypertrophy, Left Ventricular - physiopathology
Myocardium - pathology
Stroke Volume - physiology

Find related publications in this database (Keywords)
HFpEF
diastolic dysfunction
left ventricular hypertrophy
cardiac myocytes
remodeling
© Meduni Graz Impressum